Patent Assignment
Reel/Frame 031784/0833
Patent Assignment Agreement
Recorded: 2013-12-09
Pages: 58
Assignee
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
4787 LEVY STREET, MONTREAL, QUEBEC, H4R 2P9, CANADA
Covered Properties
(37)
Transcutaneous in Vivo Activation of Photosensitive Agents in Blood
Patent:
5,484,803 →
Application:
08/384,440 →
Use of Green Porphyrins to Treat Neovasculature in the Eye
Patent:
5,798,349 →
Application:
08/390,591 →
Methods of Making Liposomes Containing Hydro-Monobenzoporphyrin Photosensitizer
Patent:
5,707,608 →
Application:
08/510,573 →
Vision Through Photodynamic Therapy of the Eye
Patent:
5,756,541 →
Application:
08/613,420 →
Balloon Catheter for Photodynamic Therapy
Patent:
6,013,053 →
Application:
08/649,439 →
Use of Photodynamic Therapy for Prevention of Secondary Cataracts
Patent:
6,043,237 →
Application:
08/762,854 →
Methods, Compositions and Articles for Reducing or Preventing the Effects of Inflammation
Patent:
6,274,614 →
Application:
08/942,883 →
Vision Through Photodynamic Therapy of the Eye
Patent:
5,910,510 →
Application:
09/083,480 →
Ethylene Glycol Esters as Photoactive Agents
Patent:
5,929,105 →
Application:
09/088,524 →
Model and Method for Angiogenesis Inhibition
Patent:
6,117,862 →
Application:
09/169,735 →
Balloon Catheter for Photodynamic Therapy
Patent:
6,086,558 →
Application:
09/222,474 →
Vision Through Photodynamic Therapy of the Eye
Patent:
6,548,542 →
Application:
09/300,979 →
Ethylene Glycol Esters as Photoactive Agents
Patent:
6,153,639 →
Application:
09/313,106 →
Use of photodynamic therapy for prevention of secondary cataracts
Patent:
6,248,734 →
Application:
09/536,291 →
Ethylene Glycol Esters as Photoactive Agents
Patent:
6,756,396 →
Application:
09/588,206 →
Drug Delivery System for Hydrophobic Drugs
Methods, Compositions and Articles for Reducing or Preventing the Effects of Inflammation
Reduced Fluence Rate Pdt
Method to Prevent Vision Loss
Photodynamic Therapy of Occult Age-Related Macular Degeneration
Method for Reducing or Preventing Pdt Related Inflammation
Treatment of Macular Edema
PEG-lipid containing formulations
Application:
10/286,963 →
Publication:
US 2004/0013717
Compositions and Methods for Delivery of Photosensitive Drugs
Photodynamic Therapy For The Treatment Of Hyperactive Sebaceous Gland Disorders Using Topically Applied Hydrophobic Green Porphyrins
Application:
10/588,419 →
Publication:
US 2008/0096857
Photodynamic therapy for the treatment of acne
Application:
10/588,571 →
Publication:
US 2010/0056982
Treatment of Macular Edema
Reduced Fluence Rate Pdt
Ethylene Glycol Esters as Photoactive Agents
Immuno-Adjuvant Pdt Treatment of Metastatic Tumors
Vision Through Photodynamic Therapy of the Eye
Method for Treating Neovascularization
Drug Delivery System for Hydrophobic Drugs
Photodynamic Therapy for Conditions of the Eye
Photodynamic Therapy Laser
Method for Treating Neovascularization
Vision Through Photodynamic Therapy of the Eye
Application:
13/584,617 →
Publication:
US 2012/0310144
Related Assignments
(16)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Interest
Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
Security Interest
Jul 19, 2017
From: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043045/0959 →
Security Interest
Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
Security Interest
Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
Intellectual Property Security Agreement
Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
Security Interest
Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
Change of Name
Jan 13, 2023
From: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
To: BAUSCH HEALTH COMPANIES INC.
Reel/Frame 062389/0306 →
Assignment of Assignor's Interest
Jan 13, 2023
From: BAUSCH HEALTH COMPANIES INC.
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 062375/0428 →
Omnibus Patent Security Release Agreement (Reel/Frame 057821/0800)
Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0651 →
Omnibus Patent Security Release Agreement (Reel/Frame 045444/0634)
Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0596 →
Release of Security Interest in Specified Patents (Reel/Frame 045444/0299)
Apr 17, 2024
From: BARCLAYS BANK PLC
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0587 →
Release of Security Interest in Specified Patents (Reel/Frame 039380/0385)
Apr 17, 2024
From: BARCLAYS BANK PLC
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0578 →
Omnibus Patent Security Release Agreement (Reel/Frame 049672/0652)
Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0618 →
Release of Security Interest
Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.
Reel/Frame 070778/0199 →
Release of Security Interest
Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
Reel/Frame 073637/0001 →
Release of Security Interest
Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 073637/0222 →